Page last updated: 2024-11-10

sorivudine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID72187526
CHEMBL ID3187399
MeSH IDM0098601
PubMed CID5282192
CHEMBL ID70046
CHEBI ID32152
SCHEMBL ID82640
MeSH IDM0098601

Synonyms (70)

Synonym
cas-77181-69-2
dtxsid6057827 ,
dtxcid7031616
NCGC00262958-01
tox21_113949
CHEMBL3187399
sorivudinum [inn-latin]
(+)-1-beta-d-arabinofuranosyl-5-((e)-2-bromovinyl)uracil
(e)-1-beta-d-arabinofuranosyl-5-(2-bromoethenyl)-2,4(1h,3h)-pyrimidinedione
(e)-5-(2-bromovinyl)uridine
dru-0136
1-beta-d-arabinofuranosyl-(e)-5-(2-bromovinyl)uracil
bromovinyluridine
ccris 5285
2,4(1h,3h)-pyrimidinedione, 1-beta-d-arabinofuranosyl-5-(2-bromoethenyl)-, (e)-
5-bromovinyl-arau
1-beta-d-arabinofuranosyl-5-(2-bromovinyl)uracil
sorivudina [inn-spanish]
(e)-5-(2-bromovinyl)-1-beta-d-arabinofuranosyluracil
ja-001
arys-01
5-[(e)-2-bromovinyl]-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
2,4(1h,3h)-pyrimidinedione, 1-.beta.-d-arabinofuranosyl-5-[(1e)-2-bromoethenyl]-
1-.beta.-d-arabinofuranosyl-5-(2-bromovinyl)uracil
77181-69-2
bvau
bv ara-u
bravavir
bv-ara-u
sorivudine
bromovinyl arau
usevir
bvarau
sq-32756
brovavir
yn-72
bravavir (tn)
D01734
sorivudine (jan/usan/inn)
so 32,756
sq 32,756
so-32756
CHEMBL70046 ,
bdbm50206491
5-((e)-2-bromo-vinyl)-1-((2r,3s,4s,5r)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-4-hydroxy-1h-pyrimidin-2-one
5-[(e)-2-bromoethenyl]-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
sorivudinum
sorivudine [usan:inn:ban:jan]
sorivudina
c7voz162lv ,
unii-c7voz162lv
sorivudine [who-dd]
sorivudine [inn]
sorivudine [usan]
sorivudine [mart.]
sorivudine [mi]
sorivudine [jan]
SCHEMBL82640
AKOS025149268
CHEBI:32152
5-[(1e)-2-bromoethenyl]-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
AS-73022
DB11998
5-((e)-2-bromovinyl)-1-((2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
HY-123032
1-|a-d-arabinofuranosyl-5-[(1e)-2-bromoethenyl]-2,4(1h,3h)-pyrimidinedione
Q905418
CS-0080932
D93116
CDA18169

Research Excerpts

Overview

Sorivudine is an effective drug for the treatment of herpes zoster in HIV-infected patients. Results in accelerated cutaneous healing when compared with acyclovir therapy.

ExcerptReferenceRelevance
"Sorivudine is a promising new agent for the treatment of varicella-zoster virus infections."( Treatment of adult varicella with sorivudine: a randomized, placebo-controlled trial.
Arvin, AM; Bowler, WA; Chamberlin, CJ; Colopy, MW; Harkins, J; LaRocco, A; Oldfield, EC; Sawyer, MH; Wallace, MR, 1996
)
1.29
"Sorivudine is an effective drug for the treatment of herpes zoster in HIV-infected patients and results in accelerated cutaneous healing when compared with acyclovir therapy."( Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster St
Baum, KF; Borucki, MJ; Cloud, GA; Crumpacker, CS; DeHertogh, DA; Gnann, JW; Joseph, WP; Lalezari, JP; Mertz, GJ; Sherrill, LC; Smith, JA; Soong, SJ; Steigbigel, RT; Tyring, SK; Whitley, RJ, 1998
)
2.46

Compound-Compound Interactions

ExcerptReferenceRelevance
" Worldwide recognition of this potentially fatal drug-drug interaction led to subsequent disapproval in the US and elsewhere."( Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.
Diasio, RB, 1998
)
1.74
" These are applied for query development for identification of possible drug-drug interaction."( Drug interaction ontology (DIO) for inferences of possible drug-drug interactions.
Konagaya, A; Satou, K; Yoshikawa, S, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" One might question, as these data unfold, the relative value of drugs with such enhanced in vitro activity and oral bioavailability as compared with standard therapeutic agents."( Sorivudine: a promising drug for the treatment of varicella-zoster virus infection.
Whitley, RJ, 1995
)
1.73
" One might question, as these data unfold, the relative clinical value of antivirals with such enhanced in vitro activity and oral bioavailability as compared to standard compounds."( Sorivudine: a potent inhibitor of varicella zoster virus replication.
Whitley, RJ, 1996
)
1.74
" Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy."( New therapeutic approaches to the alphaherpesvirus infections.
Cassady, KA; Whitley, RJ, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" The ascending dosage studies have been analyzed by the BV-araU RIA, and results indicate that the values of area under the serum concentration-time curve increased proportionally with the administered dose of BV-araU up to 80 mg."( A radioimmunoassay for the new antiviral agent 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Jagoda, E; Mantha, S; Ogan, M; Stouffer, B; Tsay, HM; Tu, JI; Turabi, N; Yost, F, 1992
)
0.28
" However, E-5-(2-bromovinyl)uracil (BVU) is the major metabolite found after oral dosing in animals other than mice."( Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats.
Ashida, N; Ijichi, K; Machida, H; Watanabe, Y, 1993
)
0.29
" Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy."( New therapeutic approaches to the alphaherpesvirus infections.
Cassady, KA; Whitley, RJ, 1997
)
0.3
" All of these rats died within 10 days, whereas rats given SRV or tegafur alone under the same dosage conditions showed no appreciable change over 20 days compared with controls."( A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Kato, A; Ogura, K; Okuda, H; Takubo, H; Watabe, T, 1998
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase, cytosolicHomo sapiens (human)IC50 (µMol)500.00000.01601.21053.0000AID306718
Thymidine kinaseHuman herpesvirus 3 strain DumasIC50 (µMol)3.20003.20003.20003.2000AID306722
Thymidine kinaseHuman alphaherpesvirus 1 (Herpes simplex virus type 1)IC50 (µMol)3.60000.15004.81679.0000AID306720
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processThymidine kinase 2, mitochondrialHomo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic processThymidine kinase 2, mitochondrialHomo sapiens (human)
nucleotide biosynthetic processThymidine kinase 2, mitochondrialHomo sapiens (human)
pyrimidine nucleoside salvageThymidine kinase 2, mitochondrialHomo sapiens (human)
deoxycytidine metabolic processThymidine kinase 2, mitochondrialHomo sapiens (human)
thymidine metabolic processThymidine kinase 2, mitochondrialHomo sapiens (human)
DNA biosynthetic processThymidine kinase 2, mitochondrialHomo sapiens (human)
nucleobase-containing compound metabolic processThymidine kinase, cytosolicHomo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine metabolic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
protein homotetramerizationThymidine kinase, cytosolicHomo sapiens (human)
DNA synthesis involved in mitotic DNA replicationThymidine kinase, cytosolicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
deoxycytidine kinase activityThymidine kinase 2, mitochondrialHomo sapiens (human)
thymidine kinase activityThymidine kinase 2, mitochondrialHomo sapiens (human)
ATP bindingThymidine kinase 2, mitochondrialHomo sapiens (human)
nucleoside kinase activityThymidine kinase 2, mitochondrialHomo sapiens (human)
deoxynucleoside kinase activityThymidine kinase 2, mitochondrialHomo sapiens (human)
thymidine kinase activityThymidine kinase, cytosolicHomo sapiens (human)
protein bindingThymidine kinase, cytosolicHomo sapiens (human)
ATP bindingThymidine kinase, cytosolicHomo sapiens (human)
zinc ion bindingThymidine kinase, cytosolicHomo sapiens (human)
identical protein bindingThymidine kinase, cytosolicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
mitochondrionThymidine kinase 2, mitochondrialHomo sapiens (human)
mitochondrial matrixThymidine kinase 2, mitochondrialHomo sapiens (human)
cytoplasmThymidine kinase 2, mitochondrialHomo sapiens (human)
nucleusThymidine kinase, cytosolicHomo sapiens (human)
cytosolThymidine kinase, cytosolicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID306721Inhibition of Drosophila melanogaster dNK assessed as [methyl-3H]dThd phosphorylation2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID306719Inhibition of human TK2 assessed as [methyl-3H]dThd phosphorylation2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID218426Anti viral activity against VZV(Oka strain) in WI-38 cell monolayers.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID82698Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities.
AID82701Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID218415Anti viral activity against HCMV(AD169) in WI-38 cell monolayers1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID218427Anti viral activity against VZV(pplla strain) in WI-38 cell monolayers.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID210543Kinase activity against purified VZV Thymidine kinase (conversion of the nucleoside analogue to its diphosphate by VZV -TK )1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID44363Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities.
AID218417Anti viral activity against HSV-1(Schooler) in WI-38 cell monolayers1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID218419Anti viral activity against HSV-2(186) in WI-38 cell monolayers1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID218422Anti viral activity against VZV(9021 strain) in WI-38 cell monolayers.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID476617Inhibition of thymidine kinase 22010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
3'-[4-Aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine analogues as potent and selective inhibitors of human mitochondrial thymidine kinase.
AID82699Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities.
AID218425Anti viral activity against VZV (Kanno-Kohmura(TK-) strain) in WI-38 cell monolayers.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID306720Inhibition of HSV1 TK assessed as [methyl-3H]dThd phosphorylation2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID306722Inhibition of VZV TK assessed as [methyl-3H]dThd phosphorylation2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID218423Anti viral activity against VZV(Ellen strain) in WI-38 cell monolayers.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID82700Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
A facile, alternative synthesis of 4'-thioarabinonucleosides and their biological activities.
AID288939Inhibition of proliferation of VZV thymidine kinase expressing OSTtk-/VZVtk+ -a cells2007Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12
5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID210684Kinase activity against purified VZV Thymidine kinase (conversion of the nucleoside analogue to its monophosphate by VZV -TK )1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID218428Growth inhibitory activity against WI-38 cells1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID288940Inhibition of proliferation of VZV thymidine kinase expressing OSTtk-/VZVtk+ -b cells2007Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12
5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID306718Inhibition of human TK1 assessed as [methyl-3H]dThd phosphorylation2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
AID235624Therapeutic index of compound maesured as ratio of ID50 for WI-38 cell growth inhibition / ID50 anti-VZV (strain Ellen)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID218424Anti viral activity against VZV(Ito strain) in WI-38 cell monolayers.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of 1-cyclobutyl-5-(2-bromovinyl)uracil nucleoside analogues and related compounds.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID288938Inhibition of proliferation of thymidine kinase deficient OST cells2007Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12
5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (102)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (13.73)18.7374
1990's66 (64.71)18.2507
2000's10 (9.80)29.6817
2010's6 (5.88)24.3611
2020's6 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.79 (24.57)
Research Supply Index4.65 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials8 (8.33%)5.53%
Reviews0 (0.00%)6.00%
Reviews11 (11.46%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies6 (6.25%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
Other71 (73.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 2/3 Multi-Center, Double-Blind, Controlled Trial Comparing Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir, and Combination Topical ARYS-01 Cream /Oral Valaciclovir for Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age [NCT00652184]Phase 2300 participants (Anticipated)Interventional2008-03-31Active, not recruiting
Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous, Visceral, or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy [NCT00002358]Phase 30 participants InterventionalCompleted
Evaluation of Brovavir ( BV-ara-U; SQ 32,756 ) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV-Infected Patients [NCT00000953]Phase 2180 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]